Cassaday & Co Wealth Management’s Abbott ABT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.58M Sell
34,850
-134
-0.4% -$15.1K 0.08% 54
2025
Q4
$4.38M Buy
34,984
+72
+0.2% +$9.17K 0.09% 50
2025
Q3
$4.68M Buy
34,912
+45
+0.1% +$5.91K 0.11% 49
2025
Q2
$4.74M Sell
34,867
-370
-1% -$48.8K 0.12% 46
2025
Q1
$4.67M Sell
35,237
-562
-2% -$71.5K 0.13% 38
2024
Q4
$4.05M Buy
35,799
+694
+2% +$80.2K 0.11% 44
2024
Q3
$4M Sell
35,105
-290
-0.8% -$31.8K 0.11% 41
2024
Q2
$3.68M Sell
35,395
-211
-0.6% -$22.4K 0.12% 42
2024
Q1
$4.05M Buy
35,606
+711
+2% +$81.5K 0.13% 40
2023
Q4
$3.84M Sell
34,895
-160
-0.5% -$16K 0.13% 36
2023
Q3
$3.4M Buy
35,055
+649
+2% +$68.2K 0.14% 35
2023
Q2
$3.75M Sell
34,406
-1,281
-4% -$137K 0.15% 34
2023
Q1
$3.61M Buy
35,687
+849
+2% +$89.6K 0.15% 34
2022
Q4
$3.82M Buy
+34,838
New +$3.61M 0.18% 32

Other funds holding ABT

Cassaday & Co Wealth Management's ABT Position: Q1 2026 in Review

Cassaday & Co Wealth Management reduced its Abbott (ABT) stake by 0.38% in Q1 2026, selling an estimated $15.1K and leaving 34,850 shares worth $3.58M. The position accounts for 0.08% of the portfolio, ranked #54.

Cassaday & Co Wealth Management first reported a position in ABT in Q4 2022 and has held it in 14 quarters since. The position peaked at $4.74M in Q2 2025. 3,086 funds tracked by Wall St. Rank hold ABT as of Q1 2026.

  • Cassaday & Co Wealth Management held 34,850 shares of Abbott worth $3.58M as of Q1 2026.
  • Cassaday & Co Wealth Management sold 134 Abbott shares in Q1 2026, an estimated $15.1K.
  • Abbott made up 0.08% of Cassaday & Co Wealth Management's portfolio in Q1 2026, its #54 holding.
  • Cassaday & Co Wealth Management first reported a position in Abbott in Q4 2022 and has held it in 14 quarters since.
  • Cassaday & Co Wealth Management's Abbott position peaked at $4.74M in Q2 2025.
  • 3,086 funds tracked by Wall St. Rank held Abbott as of Q1 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.